Page 6 - Pharmacology Newsletter 2022

FACULTY
There are 22 primary faculty in the Department of Pharmacology directing research programs in cell signaling, infectious disease, cancer biology, addiction, neurodegeneration, immunology, and inflammation. These research programs are supported by over $8.5 million annually in grants and awards. We are pleased to pleased to highlight new funding earned by our faculty in 2022:
Carly Baehr
SQUARE NIH National Institute on Drug Abuse (U01 DA051658; sub-award PI) Antibody-based countermeasures against fentanyl and its analogues
SQUARE NIHNationalInstituteonDrugAbuse(UH3DA057850;sub-awardPI) Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
Justin Drake
SQUARE University of Minnesota Masonic Cancer Center
Cancer Research Translational Initiative Exceptional Translational Research Award (PI)
RET Degraders for Treating Neuroendocrine Prostate Cancer
SQUARE NIH/National Cancer Institute (PI, R01 CA269801)
RET regulation and targeting in neuroendocrine prostate cancer
SQUARE Astrin Biosciences Inc./NIH National
Cancer Institute (PI, R41/STTR CA268344)
Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug respon- siveness in prostate cancer
Tanya Freedman
SQUARE University of Minnesota Office of Academic Clinical Affairs
Faculty Research Development Award (PI)
Peptide-targeted delivery to improve the efficacy and safety of corti- costeroid drugs against rheumatoid arthritis
SQUARE University of Minnesota Masonic Cancer Center
pre-R01 Brainstorm Pilot Grant (PI)
Roles of tumor microenvironment Lyn kinase in breast cancer metas- tasis and immunotherapy
SQUARE Rheumatology Research Foundation
Innovative Research Award (PI)
LynB kinase, TLR signaling, dendritic cells, and lupus
SQUARE NIH/National Institute of Arthritis and Musculoskeletal and Skin (PI, R01 AR073966 supplement)
Roles of the Src-family kinases LynA and LynB in macrophage inflam- matory signaling
Fang Li
SQUARE NIH/National Institute of Allergy and Infectious Diseases (Co-Director, U19 AI171954)
Midwest Anti-Viral Drug Development (AViDD) Center
Michael Lipscomb
SQUARE NIH/National Institute of Allergy and Infectious Diseases (PI, R21 AI168668)
Delineating the function of MHC Class III genes in antigen presenting myeloid cell contribution to autoimmunity
SQUARE NIH/National Institute of General Medical Sciences (PI, R35 GM145290)
Deciphering the immunoregulatory network governing anti- gen presenting myeloid cells
Hai Dang Nguyen
SQUARE NIH/National Heart, Lung, and Blood Institute (PI, R01 HL 163011)
Implications of PARP1 in myelodysplastic syndromes and targeted therapy
SQUARE American Association for Cancer Research
Career Development Award to Further Diversity, Equity, and Inclusion in Cancer Research (PI)
Delineating ATR response in U2AF1 mutant hematologic malignancies
Michael Raleigh
SQUARE NIH/National Institute on Drug Abuse (UH3 DA048386) University of Washington sub-award (PI)
Vaccines for fentanyl and its derivatives: a strategy to reduce illicit use and overdose
Sade Spencer
SQUARE NIH/National Institute on Drug Abuse (PI, R21 DA050822) Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse
6 UNIVERSITY OF MINNESOTA DEPARTMENT OF PHARMACOLOGY